All News
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus
⭐️⬇️AS activity w/ or w/o MRI sacroilitis
Abs#OP0142
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
k dao KDAO2011 ( View Tweet)
Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks!
⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes
⭐️no significant changes in spine fat, bone erosion or new bone formation
Abs#OP0141
#EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
Robert B Chao, MD doctorRBC ( View Tweet)
Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow
How do you help pts manage fatigue?
Robert B Chao, MD doctorRBC ( View Tweet)
➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID.
➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz
OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
⭐️No overall increase in all CA: RTX, TOCI
⭐️Abatacept 1.21HR for all cancer, mainly NMSC
⭐️needs more data on JAKs, IL-17, IL-23
Abs#6916
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?
⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID
⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w
🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA.
OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS in SELECT-AXIS 1
⭐️Do not forgot to vaccinate patients with 1st dose of Shingrix prior to starting a JAK-i. 2nd dose can be given after start of therapy
OP0144 #EULAR2021 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Do you vaccinate ALL patients (even if less than 50 yo) with first dose of Shingrix prior to starting a JAK-i? #EULAR2021. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik
⭐️Individual socioeconomic factors associated with poorer outcomes
⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Congratulations to everyone who made it through the day today.
Shematologist, MD acweyand ( View Tweet)
Poster #POS1033: Integrated analysis of 4 IXE SPIRIT trials
IR for TEAEs ⬇️ over time
IR for SAEs low
serious infections/malignancies/MACE/IBD ⬇️
#EULAR2021 @RheumNow https://t.co/tLyXwnBDTo
Dr. Rachel Tate uptoTate ( View Tweet)
GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.
https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your EULAR IQ? #EULAR2021
https://t.co/psumBpzUc7 https://t.co/ZyD87VY8u6
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 - Day 1 Podcasts
Check out this compilation of our EULAR 2021 Day 1 broadcasts .
You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/p6n7BTsK5C https://t.co/I36SMGlb2o
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: EULAR 2021 – Day 1 Report #EULAR2021
https://t.co/igpQYMkf9l https://t.co/qESsN3meJe
Links:
Dr. John Cush RheumNow ( View Tweet)
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013, presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ
Links:
Dr. John Cush RheumNow ( View Tweet)
How common is RA ILD? @RheumNow #EULAR2021 @eular_org
Janet Pope Janetbirdope ( View Tweet)